Article Text

other Versions

PDF
Evaluating societal preferences for human papillomavirus vaccine and cervical smear test screening programme
  1. Bridgette Oteng1,
  2. Fawziah Marra1,2,
  3. Larry D Lynd1,3,
  4. Gina Ogilvie1,2,
  5. David Patrick1,2,
  6. Carlo A Marra1,3
  1. 1University of British Columbia, Vancouver, British Columbia, Canada
  2. 2British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
  3. 3Centre for Health Evaluation and Outcome Sciences, St Paul's Hospital, Vancouver, British Columbia, Canada
  1. Correspondence to Dr Carlo Marra, Faculty of Pharmaceutical Sciences, University of British Columbia, 2146 East Mall, Vancouver V5Z163, British Columbia, Canada; carlo.marra{at}bccdc.ca

Abstract

Background Cervical cancer and genital warts are diseases associated with human papillomavirus (HPV) infection. Cervical smear testing is used as a cervical cancer screening tool in most countries worldwide. The newly introduced vaccines that prevent HPV infections are the quadrivalent vaccine (Gardasil), which prevents genital warts and cervical cancer, and the bivalent vaccine (Cervarix), which prevents cervical cancer only. Public preferences for HPV vaccines and smear test screening were determined using a discrete choice experiment.

Methods Participants from across Canada completed a choice-based questionnaire to measure preferences from which willingness to pay (WTP) was calculated for the following: (1) lifetime risk of cervical cancer and genital warts, (2) frequency of smear testing, (3) need for vaccine booster, (4) target group to vaccinate, (5) frequency of side effects and (6) cost of the vaccine (from 2008). A mixed effect logistic model was used to analyse the data.

Results Of the 1157 participants, the mean age was 44 years (SD 15) and 49% were women. Respondents preferred a vaccine that gave lifelong immunity, a vaccination programme that targeted boys and girls and a vaccine that gave protection from genital warts and cervical cancer. Respondents were averse to yearly smear testing. On average, respondents were willing to pay $C53 and $C22 to avoid a 1% increase in the risk of cervical cancer and genital warts, respectively.

Conclusions Society agrees with the introduction of the HPV vaccination programme, but would prefer a programme that targets boys and girls with the quadrivalent vaccine.

  • Health Outcomes
  • HPV
  • human papilloma virus
  • vaccines
  • discrete choice experiment
  • societal preferences
  • cervical cancer
  • vaccination
  • viral vaccines

Statistics from Altmetric.com

Footnotes

  • Competing interests None declared.

  • Ethics approval This study was conducted with the approval of the University of British Columbia Behavioral Ethics Committee.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.